Methods: Patients with EGFR-mutated advanced NSCLC were randomized at 1: 1 ratio to receive erlotinib 100 mg/d or gefitinib 250 mg/d until disease progression or …
S Zhao, Z Zhang, W Fang, Y Zhang… - … Strategies in EGFR …, 2022 - books.google.com
Background: Erlotinib-based combination therapy leads to increased efficacy but also
toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment …
toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment …
[HTML][HTML] Efficacy and tolerability of erlotinib 100 mg/d vs. gefitinib 250 mg/d in EGFR-mutated advanced non-small cell lung cancer (E100VG250): an open-label …
S Zhao, Z Zhang, W Fang, Y Zhang, Z Zhang… - Frontiers in …, 2020 - frontiersin.org
Background: Erlotinib-based combination therapy leads to increased efficacy but also
toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment …
toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment …
[HTML][HTML] Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR‐mutant lung cancer: Implications for targeted therapy development
BL Lampson, M Nishino, SE Dahlberg, D Paul… - Cancer, 2016 - Wiley Online Library
BACKGROUND Erlotinib is a standard first‐line therapy for patients who have metastatic
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
Reduced-dose versus full-dose erlotinib for advanced EGFR-mutant non-small cell lung carcinoma (NSCLC): A retrospective analysis.
8074 Background: Erlotinib is an EGFR tyrosine kinase inhibitor (TKI) which is FDA-
approved at the maximum tolerated dose (MTD) of 150mg daily with dose limiting toxicities …
approved at the maximum tolerated dose (MTD) of 150mg daily with dose limiting toxicities …
[PDF][PDF] Retrospective analysis of gefitinib and erlotinib in EGFR-mutated non-small-cell lung cancer patients
C Pui, C Gregory, Z Lunqing, LI Long… - Journal of Lung …, 2017 - lungdiseasesjournal.com
Objective: The objective of this study was to compare the efficacies of gefitinib and erlotinib
in treating EGFR-mutated non-small-cell lung cancer (NSCLC) patients. Methods: 319 EGFR …
in treating EGFR-mutated non-small-cell lung cancer (NSCLC) patients. Methods: 319 EGFR …
Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim …
R Rosell, R Gervais, A Vergnenegre… - Journal of clinical …, 2011 - ascopubs.org
7503 Background: EGFR tyrosine kinase activating mutations are present in 10-26% of
NSCLC tumors and are associated with increased response to gefitinib and erlotinib …
NSCLC tumors and are associated with increased response to gefitinib and erlotinib …
Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations
N Koyama, Y Uchida - Anticancer Research, 2013 - ar.iiarjournals.org
Background: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with non-small cell …
inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with non-small cell …
[HTML][HTML] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …
K Goto, M Nishio, N Yamamoto, K Chikamori, T Hida… - Lung Cancer, 2013 - Elsevier
Introduction The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …
[HTML][HTML] A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy …
K Yamada, H Aono, Y Hosomi, H Okamoto… - European Journal of …, 2015 - Elsevier
Background Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in non-
small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth …
small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth …